###begin article-title 0
###xml 72 80 <span type="species:ncbi:9606">Patients</span>
Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease
###end article-title 0
###begin p 1
Recommended by Kurt Blaser
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
###xml 1095 1103 <span type="species:ncbi:9606">patients</span>
###xml 1226 1234 <span type="species:ncbi:9606">patients</span>
Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic disease that is associated with increased serum levels of markers of systemic inflammation. The triggering receptor expressed on myeloid cells 1 (TREM-1) is a recently identified activating receptor on neutrophils, monocytes, and macrophage subsets. TREM-1 expression is upregulated by microbial products such as the toll-like receptor ligand lipoteichoic acid of Gram-positive or lipopolysaccharides of Gram-negative bacteria. In the present study, sera from 12 COPD patients (GOLD stages I-IV,  51  6%) and 10 healthy individuals were retrospectively analyzed for soluble TREM-1 (sTREM-1) using a newly developed ELISA. In healthy subjects, sTREM-1 levels were low (median 0.25 ng/mL, range 0-5.9 ng/mL). In contrast, levels of sTREM-1 in sera of COPD patients were significantly increased (median 11.68 ng/mL, range 6.2-41.9 ng/mL, ). Furthermore, serum levels of sTREM-1 showed a significant negative correlation with lung function impairment. In summary, serum concentrations of sTREM-1 are increased in patients with COPD. Prospective studies are warranted to evaluate the relevance of sTREM-1 as a potential marker of the disease in patients with COPD.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Chronic obstructive pulmonary disease (COPD) is characterized by progressive development for the most part irreversible airflow obstruction that involves an abnormal airway inflammatory response [1]. The clinical course of COPD is typically dominated by intermittent exacerbations, responsible for the majority of the disease-associated morbidity and mortality [2, 3].
###end p 5
###begin p 6
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
In recent years COPD has more and more been characterized as a systemic inflammatory disease. Several mediators have been found increased in blood of COPD patients indicating persistent systemic inflammation [4]. The origin of this inflammatory response is unknown but several different mechanisms including smoking itself, a cytokine "spill over" from the lungs, tissue hypoxia, and genetic factors [5] or persistent bacterial colonization of the airways [6-10] have been suggested.
###end p 6
###begin p 7
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1072 1074 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 820 825 <span type="species:ncbi:10090">mouse</span>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
The triggering receptor expressed on myeloid cells (TREM-1) is a recently identified activating receptor on neutrophil granulocytes (PMN), monocytes, and macrophage subsets [11, 12]. The expression of TREM-1 is upregulated by microbial products, that is, by toll-like receptor ligands such as lipoteichoic acid (LTA) of Gram-positive or lipopolysaccharide (LPS) of Gram-negative bacteria. Ligation of TREM-1 is synergistic with TLR agonists on the activation of receptor bearing cells for the release of inflammatory mediators like TNF- and IL-8 and the initiation of neutrophil respiratory burst [11, 13]. We recently reported that a natural ligand for TREM-1 is present on platelets, although it still needs to be identified [14]. The biological significance of TREM-1 in acute inflammatory responses is documented in mouse models for septic shock, where competition of TREM-1 with a recombinant soluble TREM-1 fusion protein or an putative receptor blocking peptide derived from a conserved region of TREM-1 saved mice from lethal LPS challenge or bacterial sepsis [15-17].
###end p 7
###begin p 8
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 63 69 <span type="species:ncbi:9606">humans</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 768 776 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
TREM-1 is also produced in a soluble form [18] and released in humans after endotoxin exposition [19] or in patients suffering from severe pneumonia [20] or sepsis [21]. In these critically ill patients, elevated levels of soluble TREM-1 (sTREM-1) are detectable in bronchoalveolar lavage (BAL) fluid or in plasma, respectively, and have a high accuracy and sensitivity in detecting microbial infections as underlying disease [20, 22, 23]. In addition, the time course of sTREM-1 levels might be a useful parameter in predicting the outcome in sepsis patients [24, 25]. However, a limitation of these studies is certainly that only critically ill patients were examined. A recent study by Richeldi et al. demonstrates that an increase in sTREM-1 is also detectable in patients suffering from community acquired pneumonia caused by extracellular bacteria, but not in patients with interstitial lung disease or tuberculosis [26]. Furthermore, sTREM-1 has been associated with major abdominal surgery and peptic ulcer disease [27, 28].
###end p 8
###begin p 9
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
In the present study, we developed a sensitive enzyme-linked immunosorbent assay (ELISA) that is able to detect pg/mL amounts of sTREM-1 in serum of patients. Using this new TREM-1 specific assay, we assessed the amount of sTREM-1 released in 12 patients suffering from COPD and 10 healthy individuals for sTREM-1 and indeed found elevated levels of sTREM-1 in patients COPD, which correlated with disease severity.
###end p 9
###begin title 10
2. PATIENTS, MATERIALS, AND METHODS
###end title 10
###begin title 11
###xml 5 13 <span type="species:ncbi:9606">Patients</span>
2.1. Patients
###end title 11
###begin p 12
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
Twelve patients with COPD, all current smokers or exsmokers, were recruited on the basis of their clinical diagnosis and lung function impairment. None of the patients had lung diseases other than COPD and all were in a stable clinical condition for at least 3 month. The control group comprised 10 healthy nonsmoking individuals without the sign of airway obstruction and other significant illness. The study was approved by the local Ethics Committee.
###end p 12
###begin p 13
###xml 410 417 410 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
All patients with COPD were under treatment with inhaled -adrenoceptor agonists and/or anticholinergics, 3 patients were treated additionally with inhaled steroids, 3 with systemic steroids, and 2 with additional theophyllin, whereas the healthy control subjects did not have medication. Regarding baseline characteristics, there were no other significant differences between groups, except for lung function (Table 1).
###end p 13
###begin title 14
2.2. Assessment of lung function
###end title 14
###begin p 15
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 447 448 447 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Lung function measurements including the determination of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), residual volume (RV), intrathoracic gas volume (ITGV), and single breath diffusion capacity for carbon monoxide (DLCO) were performed following established guidelines [29-31] using standard equipment (Masterlab, Jaeger, Hochberg, Germany). Bronchodilator responses were quantified as absolute and percent increase of FEV1 measured 15 minutes after inhalation of 200  salbutamol.
###end p 15
###begin title 16
2.3. Transfectants
###end title 16
###begin p 17
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Full-length cDNA encoding TREM-1 cloned in the eukaryontic expression vector pcDNA3 (Invitrogen) were stably transfected in HEK293 cells with Fugene 6 (Roche) according to standard protocols. The TREM-1cDNAs have been described previously [11]. Transfectants were obtained after G418 selection.
###end p 17
###begin p 18
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
The production recombinant TREM-1::IgG1 fusion protein has been described previously [14].
###end p 18
###begin title 19
2.4. Monoclonal antibodies
###end title 19
###begin p 20
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 260 265 <span type="species:ncbi:9606">human</span>
TREM-1 specific monoclonal antibodies (clone 6B1) were raised by repeated immunization of BALB/c mice with a recombinant TREM-1::IgG1 fusion protein according to standard procedures. Hybridoma supernatants were first screened by ELISA against TREM-1::IgG1 and human IgG (Sigma-Aldrich, Taufkirchen), respectively. Supernatants reacting against TREM-1::IgG1, but not IgG, were subcloned twice and further screened by flow cytometry using TREM-1-transfected 293 cells. Antibodies (Abs) were purified by affinity chromatography on a protein G-Sepharose column. The mAb clones 1C5 and 6B1 were of isotype IgG1.
###end p 20
###begin title 21
2.5. Detection of soluble TREM-1 by ELISA
###end title 21
###begin p 22
###xml 328 335 <span type="species:ncbi:9606">patient</span>
For the detection of soluble TREM-1 (sTREM-1), anti-TREM-1 (6B1) mAb was coated at 0.5 g/mL in PBS, then blocked by addition of 100  of 15% BSA for 2 hours at  and washed. Afterward the standard (recombinant TREM-1::IgG1 in 7.5% BSA-PBS) and the samples were added and the plates were incubated for 2 hours at . For analysis of patient samples, sera were diluted  in 5% BSA prior to addition to the plates. After incubation, plates were washed and the biotinylated detection polyclonal Ab anti-TREM-1 (R&D Systems) at 5 g/mL in 7.5% BSA-PBS was added for 2 hours at . Plates were then washed and streptavidine-HRP ( in 7.5% BSA-PBS) was added for 1 hour at . Plates were then washed again and developed using the Tetramethylbenzidine Peroxidase Substrate System (KPL, Gaithersburg, Md). The absorbance was measured at 450 nm. Results are shown as means with SD of triplicates. The lower detection limit was defined by 2x SD of the blank values (5 pg/mL). The recovery rate was . Intraassay variation was , interassay variation was .
###end p 22
###begin title 23
2.6. Statistical procedures
###end title 23
###begin p 24
Mean values, medians, and standard deviation (SD) were computed. sTREM-1 levels were compared between groups using Mann-Whitney-U test. Lung function and other values were compared between groups using unpaired -test. Correlation analysis was performed by Spearman's rank correlation. Statistical significance was assumed for .
###end p 24
###begin title 25
3. RESULTS
###end title 25
###begin title 26
3.1. Detection of sTREM-1 in serum by ELISA
###end title 26
###begin p 27
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 242 250 242 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 97 104 <span type="species:ncbi:9606">patient</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
To evaluate the newly developed assay TREM-1-IgG recombinant human TREM-1::IgG1 and serum form a patient with sepsis were analyzed in serial dilutions since high levels of sTREM-1 have been described in sepsis previously [22]. As depicted in Figure 1, the assay allowed the detection of sTREM-1 down to 5 pg/mL sTREM-1 concluding that this new ELISA protocol is a suitable tool to investigate the significance of sTREM-1 in patients.
###end p 27
###begin title 28
###xml 45 53 <span type="species:ncbi:9606">patients</span>
3.2. Serum levels of sTREM-1 are elevated in patients with COPD
###end title 28
###begin p 29
###xml 56 63 56 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 147 154 147 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">32</xref>
###xml 496 503 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 603 604 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 826 834 826 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
None of the control patients showed airway obstruction (Table 1), whereas COPD patients showed a significantly decreased FEV1 and FEV1% predicted (Table 1). According to GOLD criteria 2, patients were categorized as stage I (mild), 3 patients as stage II (moderate), 6 patients as stage III (severe) and 1 patients as stage IV (very severe) [32]. COPD patients also showed a significant increase in RV () as well as ITGV () and a significant decrease in DLCO () compared to the control subjects (Table 1). None of the COPD patients showed a positive response to salbutamol, defined as an increase in FEV1 of at least 15% and 200 mL. Serum levels of sTREM-1 were significantly () increased in patients with COPD compared to controls. In contrast, in healthy subjects sTREM-1 was detectable in serum samples of only 6 subjects (Figure 2).
###end p 29
###begin title 30
3.3. Relationship between serum levels of sTREM-1 and clinical parameters
###end title 30
###begin p 31
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 90 98 90 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
Levels of sTREM-1 in serum were correlated with absolute FEV1 (, ), FEV1% predicted (, ) (Figure 3) and FEV1% VC (, ). Also significant correlations were detected to RV (, ), DLCO (, ) and VC % predicted (, ). No relationship was found between sTREM-1 and BMI (, ), age of the patient (, ), height (, ), or weight (, ).
###end p 31
###begin p 32
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Due to the limited number of patients in our study, it was not possible to analyze correlations between lung function parameter and sTREM-1 levels.
###end p 32
###begin title 33
4. DISCUSSION
###end title 33
###begin p 34
###xml 75 83 <span type="species:ncbi:9606">patients</span>
In the present study, we show that sTREM-1 levels in serum are elevated in patients with COPD compared to healthy, nonsmoking controls. Furthermore, we demonstrate that serum levels of sTREM-1 are correlated with disease severity.
###end p 34
###begin p 35
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">33</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">34</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">35</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">36</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">37</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">38</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">39</xref>
###xml 1105 1106 1105 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">40</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 991 999 <span type="species:ncbi:9606">patients</span>
COPD is a multicomponent disease which includes inflammatory changes in the lung. Inflammatory cells in lungs of patients with COPD are mainly neutrophil granulocytes and inflammation in the lung is more pronounced with worse lung function [33]. Also, numbers of neutrophils in sputum correlate with disease progression [34]. In many patients, COPD has also significant systemic consequences. This includes loss of lean bodymass, cardiovascular effects, osteoporosis, muscle wasting but also a systemic inflammatory response. Indeed, in patients with COPD, even during stable disease, there is an increased number of leukocytes in peripheral blood [35, 36] Peripheral neutrophils from patients with COPD show enhanced chemotaxis and extracellular proteolysis [37], produce more reactive oxygen species [38], and enhanced expression of several surface adhesion molecules [39]. Also increased levels of TNF-, IL-6, IL-8, C-reactive protein, and fibrinogen in serum can be detected in serum of patients with stable COPD and some of these systemic inflammatory changes seem to be related to disease severity [4] and correlate with severity of systemic consequences like muscle wasting [40].
###end p 35
###begin p 36
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">41</xref>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1470 1472 1470 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">42</xref>
###xml 1677 1679 1677 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
###xml 1090 1098 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
###xml 1345 1353 <span type="species:ncbi:9606">patients</span>
In the present study, we describe a new ELISA for the detection of sTREM-1 in serum. In contrast, most previous studies have used an immunodot blot technique for the detection of sTREM-1 [22, 25, 41]. This technique allows the sensitive detection of sTREM-1 in body fluids. However, for assessment of sTREM-1 in a clinical routine setting detection by sandwich ELISA has the advantage that greater sample numbers may be processed simultaneously with increased specificity. Therefore, we developed a new sensitive ELISA using a monoclonal antibody to capture sTREM-1 in sera of patients and a polyclonal anti-TREM-1 for detection. Using our new sandwich-ELISA protocol, we established a standard laboratory method for the sensitive and specific detection of sTREM-1 in body fluids avoiding the pitfalls and potential disadvantages associated with the immunodot blot technique used so far. When analyzing serum samples from patients with stable COPD, we were able to detect sTREM-1 in all samples. In contrast, in samples from healthy control subjects sTREM-1 was only detectable in 6 of the patients and only in very low amounts. In line with previous data obtained from patients suffering from severe inflammatory disorders like pneumonia or sepsis [22-24], our data indicate that sTREM-1 might be a result of neutrophil activation also in COPD patients. The current view in terms of the pathophysiology suggests that sTREM-1 is an anti-inflammatory mediator of sepsis [42], released as a counter regulator of TREM-1 mediated activation. Our recent results demonstrating that sTREM-1 interferes with the TREM-1/ligand interaction of neutrophil and platelets support this view [14].
###end p 36
###begin p 37
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">41</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Previous studies have described increased levels of sTREM-1 in patients with sepsis [22], pneumonia [20] but also exacerbated asthma and COPD. By using an immunoblot technique, Phua et al. found increased levels of sTREM-1 especially in patients with COPD during an Anthonisen-type 1 exacerbation [41].
###end p 37
###begin p 38
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">43</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">44</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
The authors speculated that the patients with type 1 exacerbation shad higher airway bacterial loads, which triggered systemic inflammation and increased sTREM-1 levels [43, 44]. In the present study, increased levels of sTREM-1, measured by ELISA, were detected even in patients with stable disease. This could be due to an increased sensitivity of the newly introduced ELISA.
###end p 38
###begin p 39
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">44</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">45</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">47</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
Potential explanations for the increased levels of sTREM-1 observed in this group of stable patients with COPD could be persistent bacterial colonization of the airways, which has been demonstrated by several groups [6-9]. These colonizations can be associated with elevated levels of inflammatory mediators like IL-8, LTB4, and TNF- in the lungs of patients with clinically stable disease [10]. In addition, increased plasma fibrinogen and IL-6 levels are detectable in these bacterially colonized patients suggesting that colonization contributes to systemic inflammation [44]. In patients with more advanced disease, higher levels of serum CRP have been described, suggesting increased systemic inflammatory reaction [45-47]. As sTREM-1 can be induced by increased systemic inflammation [20, 23, 24] the increased sensitivity of our ELISA assay could be the reason for increased levels of sTREM-1 detected in the present study population.
###end p 39
###begin p 40
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
Additionally, we found a correlation of sTREM-1 levels in serum with disease severity, described by impaired lung function, in the COPD group. This was the case when absolute and relative values of FEV1 as markers for airway obstruction, RV for hyperinflation, and also diffusion capacity as a marker for emphysema were analyzed. No correlations were found for age, height, weight, or BMI. Also levels of sTREM-1 in serum were independent for medication used by patients. Some of the patients with more severe disease (GOLD stadium III-IV) treated with systemic steroid still showed increased levels of sTREM-1 in serum. Although this analysis is somewhat limited by low numbers of patients and control sTREM-1 may yet be another systemic marker correlated with disease severity.
###end p 40
###begin p 41
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 331 338 <span type="species:ncbi:9606">patient</span>
In summary we show increased serum levels of sTREM-1 in patients with clinical stable COPD, and a correlation between serum levels and disease severity. sTREM-1 might be a useful marker for systemic inflammation in patients with COPD. Further prospective studies are needed to evaluate the true diagnostic value of sTREM-1 in this patient population.
###end p 41
###begin title 42
ACKNOWLEDGMENTS
###end title 42
###begin p 43
The authors thank Andrea Drescher and Annekatrin Meinl for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft (RA988/2-1/2 and RA988/3-1 to H. Schild and M. P. Radsak and SFB 548, A11 to C. Taube). M. P. Radsak and C. Taube contributed equally to this work.
###end p 43
###begin article-title 44
The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease
###end article-title 44
###begin article-title 45
Mechanisms and experimental models of chronic obstructive pulmonary exacerbations
###end article-title 45
###begin article-title 46
Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease
###end article-title 46
###begin article-title 47
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
###end article-title 47
###begin article-title 48
Systemic effects of chronic obstructive pulmonary disease
###end article-title 48
###begin article-title 49
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis
###end article-title 49
###begin article-title 50
Bronchial inflammation: its relationship to colonizing microbial load and -antitrypsin deficiency
###end article-title 50
###begin article-title 51
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease
###end article-title 51
###begin article-title 52
Airway inflammation and etiology of acute exacerbations of chronic bronchitis
###end article-title 52
###begin article-title 53
Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD
###end article-title 53
###begin article-title 54
Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes
###end article-title 54
###begin article-title 55
###xml 100 105 <span type="species:ncbi:9606">human</span>
Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine
###end article-title 55
###begin article-title 56
Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival
###end article-title 56
###begin article-title 57
TREM-1 ligand expression on platelets enhances neutrophil activation
###end article-title 57
###begin article-title 58
TREM-1 amplifies inflammation and is a crucial mediator of septic shock
###end article-title 58
###begin article-title 59
###xml 110 116 <span type="species:ncbi:10090">murine</span>
A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis
###end article-title 59
###begin article-title 60
###xml 86 92 <span type="species:ncbi:10090">murine</span>
Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock
###end article-title 60
###begin article-title 61
TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development
###end article-title 61
###begin article-title 62
###xml 109 114 <span type="species:ncbi:9606">human</span>
Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia
###end article-title 62
###begin article-title 63
Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia
###end article-title 63
###begin article-title 64
Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis
###end article-title 64
###begin article-title 65
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis
###end article-title 65
###begin article-title 66
Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia and severe sepsis
###end article-title 66
###begin article-title 67
Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia
###end article-title 67
###begin article-title 68
Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis
###end article-title 68
###begin article-title 69
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections
###end article-title 69
###begin article-title 70
Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease
###end article-title 70
###begin article-title 71
###xml 102 107 <span type="species:ncbi:9606">human</span>
Production of soluble triggering receptor expressed on myeloid cells by lipopolysaccharide-stimulated human neutrophils involves de novo protein synthesis
###end article-title 71
###begin article-title 72
Standardisation of the single-breath determination of carbon monoxide uptake in the lung
###end article-title 72
###begin article-title 73
Standardisation of spirometry
###end article-title 73
###begin article-title 74
Standardisation of the measurement of lung volumes
###end article-title 74
###begin article-title 75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary
###end article-title 75
###begin article-title 76
The nature of small-airway obstruction in chronic obstructive pulmonary disease
###end article-title 76
###begin article-title 77
Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study
###end article-title 77
###begin article-title 78
###xml 78 86 <span type="species:ncbi:9606">patients</span>
The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis
###end article-title 78
###begin article-title 79
The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults
###end article-title 79
###begin article-title 80
Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis
###end article-title 80
###begin article-title 81
Enhanced neutrophil response in chronic obstructive pulmonary disease
###end article-title 81
###begin article-title 82
Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease
###end article-title 82
###begin article-title 83
The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group
###end article-title 83
###begin article-title 84
Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections
###end article-title 84
###begin article-title 85
Soluble form of the triggering receptor expressed on myeloid cells 1: an anti-inflammatory mediator?
###end article-title 85
###begin article-title 86
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
###end article-title 86
###begin article-title 87
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease
###end article-title 87
###begin article-title 88
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease
###end article-title 88
###begin article-title 89
Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination
###end article-title 89
###begin article-title 90
Raised CRP levels mark metabolic and functional impairment in advanced COPD
###end article-title 90
###begin p 91
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 128 133 <span type="species:ncbi:9606">human</span>
###xml 199 206 <span type="species:ncbi:9606">patient</span>
ELISA for sTREM-1. (a) Titration of recombinant human TREM-1::IgG1 either in the absence (filled symbols) or presence of normal human serum (open symbols). (b) Serial dilution of serum from a septic patient. The  values are the correlation coefficients of the depicted data.
###end p 91
###begin p 92
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Concentration of sTREM-1 in serum of healthy controls (controls) and patients with COPD.
###end p 92
###begin p 93
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
Relationship between sTREM-1 serum levels and absolute FEV1(panel A), FEV1% predicted (panel B), residual volume (RV) % predicted (panel C), and diffusion capacity (DLCO) % predicted (panel D). Control subjects are represented by open circles, patients with COPD by closed circles.
###end p 93
###begin p 94
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' characteristics ( ND not done).
###end p 94
###begin p 95
* For abbreviations, see text. Mean values  SD are given. For sTREM-1 median and range are given  regarding the comparison between groups.
###end p 95

